Corresponding Author: Jesse L. Goodman, MD, MPH, Georgetown University, 3900 Reservoir Rd, Washington, DC 20057 (firstname.lastname@example.org).
Published Online: April 16, 2020. doi:10.1001/jama.2020.6434
Conflict of Interest Disclosures: Dr Goodman reported receiving travel and meeting expenses from US Pharmacopeia; compensation (including equity) for service as a board member and travel and meeting expenses from GlaxoSmithKline; and compensation for service as a board member, equity options, and reimbursement for travel expenses from Intellia Therapeutics outside the submitted work and was previously the US Food and Drug Administration’s chief scientist. Dr Borio is the vice president of In-Q-Tel and was previously director for medical and biodefense preparedness policy at the US National Security Council and, before that, the acting chief scientist at the US Food and Drug Administration.
Disclaimer: The views expressed are solely those of the authors and not those of any institutions they are or have been affiliated with.
Additional Contributions: We thank Nicole Lurie, MD, MSPH (Coalition for Epidemic Preparedness Innovations), for helpful comments.
US Food and Drug Administration. Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease. Published March 28, 2020. Accessed April 13, 2020. https://www.fda.gov/media/136534/download
Q , Wang
Y , Qi
C , Shen
L , Li
J . Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol
. Published online February 18, 2020. doi:10.1002/jmv.25733PubMedGoogle Scholar